{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T08:14:35Z","timestamp":1697444075909},"reference-count":16,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2013,4,18]],"date-time":"2013-04-18T00:00:00Z","timestamp":1366243200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cardiovascular Therapeutics"],"published-print":{"date-parts":[[2013,6]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p><jats:bold>Aims:<\/jats:bold> Angiotensin receptor blockers (ARBs) exert favorable effects on the vascular system, which are not directly related to hypertension lowering function. The no\u2010reflow phenomenon determines the prognosis in patients after acute myocardial infarction (AMI). Early ARB treatment has many beneficial effects on the prognosis after AMI. In this study, we tested the hypothesis that ARB treatment before admission would have beneficial effects on the development of the no\u2010reflow phenomenon after infarction. <jats:bold>Methods:<\/jats:bold> We investigated 276 consecutive patients with AMI undergoing successful primary percutaneous coronary intervention (PCI). No\u2010reflow was defined as thrombolysis in myocardial infarction (TIMI) flow grade &lt;3, which was determined by the TIMI frame count method using angiographic images obtained just after PCI and stenting. <jats:bold>Results:<\/jats:bold> Compared with patients without ARB treatment, patients with ARB had more frequently hypertension and ST resolution (<jats:italic>P<\/jats:italic> &lt; 0.05), but no significant difference was found in the other clinical characteristics (age, sex, Hyperlipidaemia, Diabetes mellitus, etc) between the two groups. A total of 51 patients receiving chronic ARB treatment before admission have lower incidence of the no\u2010reflow phenomenon than those without chronic ARB treatment (8.7% and 26.7%, <jats:italic>P<\/jats:italic>= 0.003). However, the incidence of the no\u2010reflow phenomenon between the patients with and without hypertension had no significant difference. Multivariable logistic regression analysis revealed that ARB pretreatment was a significant predictor of the no\u2010reflow phenomenon, whereas blood pressure was found to be insignificant. <jats:bold>Conclusion:<\/jats:bold> Chronic pretreatment of ARB is associated with the reduction of the no\u2010reflow phenomenon in patients with reperfused AMI and could preserve microvascular integrity after AMI independent of blood pressure lowering, which may contribute to better functional recovery.<\/jats:p>","DOI":"10.1111\/j.1755-5922.2012.00314.x","type":"journal-article","created":{"date-parts":[[2012,4,10]],"date-time":"2012-04-10T13:37:37Z","timestamp":1334065057000},"source":"Crossref","is-referenced-by-count":8,"title":["Effect of Chronic Pretreatment of Angiotensin\u2010Converting Receptor Blocker on No\u2010Reflow Phenomenon in Patients with Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention"],"prefix":"10.1111","volume":"31","author":[{"given":"Tao","family":"Hu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hai\u2010Chang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ru\u2010Tao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"An\u2010Lin","family":"Lv","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rong\u2010Hua","family":"Luan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheng\u2010Xiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"He\u2010Xiang","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheng\u2010Hai","family":"Xia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ling","family":"Tao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,4,18]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0808276"},{"key":"e_1_2_6_3_2","first-page":"57","article-title":"Predictive factors of myocardial reperfusion in patients with anterior wall acute myocardial infarction","volume":"15","author":"Olszowska M","year":"2008","journal-title":"Cardiol J"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF03256579"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1080\/17482940902978061"},{"key":"e_1_2_6_6_2","first-page":"21","article-title":"Results of the ONTARGET and TRANSCEND studies: an update and discussion","volume":"5","author":"Fitchett D","year":"2009","journal-title":"Vasc Health Risk Manag"},{"key":"e_1_2_6_7_2","first-page":"121","article-title":"The diagnosis and treatment of the no\u2010reflow phenomenon in patients with myocardial infarction undergoing percutaneous coronary intervention","volume":"13","author":"Ramjane K","year":"2008","journal-title":"Exp Clin Cardiol"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.4244\/EIJV4I2A32"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/ccd.21715"},{"key":"e_1_2_6_10_2","first-page":"374","article-title":"Pharmaceutical interventions for the management of no\u2010reflow","volume":"20","author":"Fischell TA","year":"2008","journal-title":"J Invasive Cardiol"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1080\/17482940701744318"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1751-7141.2008.00004.x"},{"key":"e_1_2_6_13_2","first-page":"69","article-title":"Large clinical trials of ARB in Japan and its reflection to new guidelines","volume":"67","author":"Matsuoka H","year":"2009","journal-title":"Nippon Rinsho"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehn416"},{"key":"e_1_2_6_15_2","first-page":"812","article-title":"Pharmacological characteristics of ARB and potential strategy to develop novel ARB","volume":"67","author":"Kim\u2010Mitsuyama S","year":"2009","journal-title":"Nippon Rinsho"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.2147\/VHRM.S3141"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00392-009-0756-z"}],"container-title":["Cardiovascular Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1755-5922.2012.00314.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1755-5922.2012.00314.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T14:33:24Z","timestamp":1697380404000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1755-5922.2012.00314.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4,18]]},"references-count":16,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,6]]}},"alternative-id":["10.1111\/j.1755-5922.2012.00314.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1755-5922.2012.00314.x","archive":["Portico"],"relation":{},"ISSN":["1755-5914","1755-5922"],"issn-type":[{"value":"1755-5914","type":"print"},{"value":"1755-5922","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,4,18]]}}}